Benign Infantile Epilepsy Gene Panel in UAE | 4800 AED | DHA Licensed

Executive Summary & Core Metrics

Guaranteed Diagnostic Precision: 99.9% analytical sensitivity via ISO 9001:2015 certified next‑generation sequencing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection, available daily from 8 AM to 11 PM.
Post‑Test Clinical Guidance: Complimentary telephonic interpretation session with a Consultant Medical Geneticist.
Insurance Verification: Direct billing confirmation via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The Benign Infantile Epilepsy Gene Panel is a next‑generation sequencing (NGS) test that analyses over 20 genes (e.g., KCNQ2, KCNQ3, SCN1A) linked to self‑limiting neonatal and infantile epilepsies. It enables precise diagnosis, guides antiepileptic drug selection and provides recurrence risk counselling for affected families.

Feature	Our Benign Infantile Epilepsy Panel	Closest Alternative
Precision	>99.9% analytical sensitivity (NGS with copy‑number variant detection)	Single‑gene Sanger sequencing; misses >60% of pathogenic variants
Method	Next‑Generation Sequencing (NGS) with validated bioinformatic pipeline	Sequential single‑gene testing; often incomplete and delayed
Turnaround	4–6 weeks from sample receipt	8–16 weeks for equivalent information when genes tested sequentially

Physician Insight & Safety Protocols

“Families facing a new seizure diagnosis in their infant carry immense worry. This targeted gene panel delivers definitive answers, enabling precise therapeutic decisions and offering much‑needed recurrence risk clarity. Results must always be integrated with the complete clinical and neurological evaluation.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403

Medication Continuation Advisory

⚠️ Never discontinue prescribed antiepileptic drugs without explicit neurologist approval. Abrupt withdrawal can trigger breakthrough seizures and clinical deterioration. The gene panel does not require fasting or any change to the child’s medication schedule.

Safety & Exclusion Criteria

Prescription Requirement: A valid physician order is mandatory. For pre‑surgical clearance, pregnancy‑related genetic counselling or travel fitness, the laboratory may accept direct referral with supporting documentation – please contact our team before sample collection.
Sample Adequacy: Whole blood specimens must be collected in EDTA tubes. Rejected if haemolysed, clotted or insufficient volume (<2 mL). All samples require proper labeling and cold‑chain handling.
Informed Consent: Written consent is required in accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. For minors, parental or legal guardian consent is mandatory under UAE federal law.
Emergency Red Flags: If the child experiences a prolonged seizure (>5 minutes), breathing difficulty or decreased consciousness, proceed immediately to the nearest emergency department. A negative panel result does not exclude epilepsy; continue regular follow‑up with your neurologist.

Patient FAQ & Clinical Guidance

1. What conditions does the Benign Infantile Epilepsy Gene Panel detect?

This NGS panel identifies pathogenic variants in genes such as KCNQ2, KCNQ3 and SCN1A that cause self‑limiting (benign) neonatal and infantile epilepsies, distinguishing them from severe epileptic encephalopathies and guiding treatment and prognosis.

2. Do I need to stop anti‑seizure medication before the blood draw?

No. Never discontinue prescribed antiepileptic drugs without explicit approval from your child’s neurologist. The gene panel does not require fasting, medication changes, or any special preparation.

3. How reliable are the results, and will my insurance cover the 4800 AED fee?

Our ISO 9001:2015 certified laboratory delivers 99.9% analytical sensitivity for all reported sequence variants and copy‑number changes, in full alignment with DHA molecular testing standards. We verify insurance coverage directly via WhatsApp before proceeding.

UAE Regulatory & Data Privacy Adherence

Data Protection & Health Information Governance: DNA Labs UAE operates under the framework of Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled and processed solely for diagnostic purposes with explicit patient consent.

Clinical Safety & Medical Liability: All laboratory procedures and patient safety protocols adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring the highest standards of care, informed consent and professional accountability.

Clinical & Logistical Metadata

Test Name	Benign Infantile Epilepsy Gene Panel
Price (AED)	4,800
Turnaround Time	4–6 weeks
Sample Type / Matrix	Peripheral whole blood (EDTA tube) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM
Methodology Used	Next‑Generation Sequencing (NGS) with copy‑number variant detection
ICD-10-CM Code	G40.30
LOINC Code	101369-5
DHA Facility License & Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE